Ameriprise
HZNP

Ameriprise’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ameriprise’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-120,430
Closed -$14M – 4034
2023
Q3 		$14M Sell
120,430
-606,784
-83% -$65.2M ﹤0.01% 1457
2023
Q2 		$74.8M Buy
727,214
+474,912
+188% +$50.1M 0.02% 600
2023
Q1 		$27.5M Sell
252,302
-1,774,419
-88% -$196M 0.01% 1060
2022
Q4 		$231M Sell
2,026,721
-1,043,852
-34% -$86.7M 0.08% 261
2022
Q3 		$189M Buy
3,070,573
+501,561
+20% +$35M 0.07% 288
2022
Q2 		$204M Buy
2,569,012
+1,248,021
+94% +$118M 0.07% 292
2022
Q1 		$139M Sell
1,320,991
-817,142
-38% -$79.6M 0.04% 420
2021
Q4 		$230M Sell
2,138,133
-417,027
-16% -$45.5M 0.06% 315
2021
Q3 		$280M Sell
2,555,160
-231,616
-8% -$24M 0.09% 239
2021
Q2 		$261M Buy
2,786,776
+56,449
+2% +$5.19M 0.08% 259
2021
Q1 		$252M Buy
2,730,327
+1,283,244
+89% +$108M 0.08% 243
2020
Q4 		$106M Sell
1,447,083
-104,930
-7% -$7.8M 0.04% 455
2020
Q3 		$121M Buy
1,552,013
+164,073
+12% +$11.3M 0.05% 372
2020
Q2 		$77.5M Sell
1,387,940
-651,243
-32% -$27.9M 0.03% 465
2020
Q1 		$60.4M Sell
2,039,183
-1,218,599
-37% -$41.2M 0.03% 476
2019
Q4 		$118M Sell
3,257,782
-253,315
-7% -$7.77M 0.05% 354
2019
Q3 		$95.7M Buy
3,511,097
+98,076
+3% +$2.54M 0.04% 419
2019
Q2 		$82.1M Buy
3,413,021
+2,155,832
+171% +$54.7M 0.04% 483
2019
Q1 		$33.2M Sell
1,257,189
-410,860
-25% -$9.74M 0.02% 852
2018
Q4 		$32.6M Sell
1,668,049
-301,406
-15% -$5.91M 0.02% 796
2018
Q3 		$38.6M Sell
1,969,455
-248,297
-11% -$4.72M 0.01% 878
2018
Q2 		$36.7M Sell
2,217,752
-426,542
-16% -$6.5M 0.02% 815
2018
Q1 		$37.5M Buy
2,644,294
+280,930
+12% +$4.15M 0.02% 790
2017
Q4 		$34.5M Buy
2,363,364
+235,670
+11% +$3.31M 0.02% 741
2017
Q3 		$27M Buy
2,127,694
+1,717,841
+419% +$21.8M 0.01% 870
2017
Q2 		$4.87M Buy
+409,853
New +$5.1M ﹤0.01% 2094
2016
Q4 		– Sell
-52,210
Closed -$947K – 3990
2016
Q3 		$947K Buy
+52,210
New +$1.02M ﹤0.01% 2937
2015
Q4 		– Sell
-50,225
Closed -$996K – 3968
2015
Q3 		$996K Sell
50,225
-145,230
-74% -$4.59M ﹤0.01% 2980
2015
Q2 		$6.79M Buy
195,455
+88,064
+82% +$2.69M ﹤0.01% 1920
2015
Q1 		$2.79M Sell
107,391
-129,252
-55% -$2.37M ﹤0.01% 2420
2014
Q4 		$3.05M Sell
236,643
-42,867
-15% -$537K ﹤0.01% 2346
2014
Q3 		$3.43M Sell
279,510
-42,557
-13% -$495K ﹤0.01% 2258
2014
Q2 		$5.09M Buy
322,067
+247,024
+329% +$3.53M ﹤0.01% 2065
2014
Q1 		$1.14M Buy
75,043
+74,503
+13,797% +$841K ﹤0.01% 2679
2013
Q4 		$4K Sell
540
-3,212
-86% -$17.3K ﹤0.01% 4706
2013
Q3 		$13K Buy
3,752
+280
+8% +$738 ﹤0.01% 4734
2013
Q2 		$9K Buy
+3,472
New +$8.33K ﹤0.01% 4874

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Ameriprise's HZNP Position: Q4 2023 in Review

Ameriprise sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 120,430 shares — an estimated $14M sold.

Ameriprise first reported a position in HZNP in Q2 2013 and held it in 37 quarters. The position peaked at $280M in Q3 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Ameriprise reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Ameriprise sold 120,430 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $14M.
  • Ameriprise first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 37 quarters.
  • Ameriprise's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $280M in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Ameriprise's 13F filing for Q4 2023, filed 14 Feb 2024.